Agrin binds α-synuclein and modulates α-synuclein fibrillation

Glycobiology

Volumn 15, Issue 12, 2005, Pages 1320-1331

  Liu, I Hsuan ^a   Uversky, Vladimir N ^b   Munishkina, Larissa A ^b   Fink, Anthony L ^b   Halfter, Willi ^c   Cole, Gregory J ^a  

^a NORTH CAROLINA CENTRAL UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

synuclein; Agrin; Heparan sulfate proteoglycan; Parkinson's disease; Protein conformational disorders

Indexed keywords

AGRIN; ALPHA SYNUCLEIN; HEPARAN SULFATE;

ARTICLE; BETA SHEET; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; FIBER; HUMAN; HUMAN CELL; HUMAN TISSUE; LEWY BODY; MOLECULAR MECHANICS; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; SOLUBILITY; SUBSTANTIA NIGRA;

AGRIN; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; CELL DEATH; CHICKENS; CIRCULAR DICHROISM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPARITIN SULFATE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LEWY BODIES; MICROSCOPY, ELECTRON, TRANSMISSION; NEURODEGENERATIVE DISEASES; NEURONS; PARKINSON DISEASE; PRIONS; PROTEIN BINDING; PROTEIN CONFORMATION; RECOMBINANT PROTEINS; SOLUBILITY; SUBSTANTIA NIGRA; SYNUCLEINS; TIME FACTORS;

EID: 28444458083     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwj014     Document Type: Article

References (75)

1. Ancsin, J.B. (2003) Amyloidogenesis: Historical and modern observations point to heparan sulfate proteoglycans as a major culprit. Amyloid, 10, 67-79.
2. Bayer, T.A., Jakala, P., Hartmann, T., Havas, L., McLean, C., Culvenor, J.G., Li, Q.X., Masters, C.L., Falkai, P., and Beyreuther, K. (1999) Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores. Neurosci. Lett., 266, 213-216.
3. Berzin, T.M., Zipser, B.D., Rafii, M.S., Kuo-Leblanc, V., Yancopoulos, G.D., Glass, D.J., Fallon, J.R., and Stopa, E.G. (2000) Agrin and microvascular damage in Alzheimer's disease. Neurobiol. Aging, 21, 349-355.
4. Cai, X.D., Golde, T.E., and Younkin, S.G. (1993) Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. Science, 259, 514-516.
5. Carrell, R.W. and Lomas, D.A. (1997) Conformational disease. Lancet, 350, 134-138.
6. Castillo, G.M., Cummings, J.A., Yang, W., Judge, M.E., Sheardown, M.J., Rimvall, K., Hansen, J.B., and Snow, A.D. (1998) Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid peptide (amylin) fibril formation. Diabetes, 47, 612-620.
7. Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A.Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., and Slekoe, D.J. (1992) Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Nature, 360, 762-674.
8. Cohen, N.A., Kaufmann, W.E., Worley, P.F., and Rupp, F. (1997) Expression of agrin in the developing and adult rat brain. Neuroscience, 76, 581-596.
9. Cohlberg, J.A., Li, J., Uversky, V.N., and Fink, A.L. (2002) Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro. Biochemistry, 41, 1502-1511.
10. Cole, G.J. and Liu, I.-H. (in press) Glycosaminoglycans, proteoglycans and conformational disorders. In Uversky, V. and Fink, A.L. (eds), Protein Misfolding, Aggregation and Conformational Diseases, Vol. I, Protein Aggregation and Conformational Diseases. Kluwer Academic/Plenum Publishers, New York.
11. Cotman, S.L., Halfter, W., and Cole, G.J. (1999) Identification of extracellular matrix ligands for the heparan sulfate proteoglycan agrin. Exp. Cell Res., 249, 54-64.
12. Cotman, S.L., Halfter, W., and Cole, G.J. (2000) Agrin binds to β-amyloid (Aβ), accelerates Aβ fibril formation, and is localized to Aβ deposits in Alzheimer's disease brain. Mol. Cell Neurosci., 15, 183-198.
13. Denzer, A.J., Gesemann, M., Schumacher, B., and Ruegg, M.A. (1995) An amino-terminal extension is required for the secretion of chick agrin and its binding to extracellular matrix. J. Cell Biol., 131, 1547-1560.
14. Donahue, J.E., Berzin, T.M., Rafii, M.S., Glass, D.J., Yancopoulos, G.D., Fallon, J.R., and Stopa, E.G. (1999) Agrin in Alzheimer's disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma. Proc. Natl. Acad. Sci. U. S. A., 96, 6468-6472.
15. El-Agnaf, O.M., Jakes, R., Curran, M.D., and Wallace, A. (1998a) Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett., 440, 67-70.
16. El-Agnaf, O.M.A., Jakes, R., Curran, M.D., Middleton, D., Ingenito, R., Bianchi, E., Pessi, A., Neill, D., and Wallace, A. (1998b) Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid-like filaments. FEBS Lett., 440, 71-75.
17. Glenner, G.G. and Wong, C.W. (1984) Alzheimer's disease and Downs's syndrome: Sharing a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun., 122, 1131-1135.
18. Goldberg, M.S. and Lansbury, P.T. Jr. (2000) Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat. Cell Biol., 2, E115-E119.
19. Gosavi, N., Lee, H.-J., Lee, J.S., Patel, S., and Lee, S.-J. (2002) Golgi fragmentation occurs in the cells with prefibrillar α-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem., 277, 48984-48992.
20. Halfter, W., Schurer, B., Yip, J., Yip, L., Tsen, G., Lee, J.-A., and Cole, G.J. (1997) Distribution and substrate properties of agrin, a heparan sulfate proteoglycan of developing axonal pathways. J. Comp. Neurol., 383, 1-17.
21. Hartley, D.M., Walsh, D.M., Ye, C.P., Diehl, T., Vasquez, S., Vassilev, P.M., Teplow, D.B., and Selkoe, D.J. (1999) Protofibrillar intermediates of amyloid-β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci., 19, 8876-8884.
22. Herndon, M.E., Stipp, C.S., and Lander, A.D. (1999) Interactions of neural glycosaminoglycans and proteoglycans with protein ligands: assessment of selectivity, heterogeneity and the participation of core proteins in binding. Glycobiology, 2, 143-155.39.
23. Knox, S., Merry, C., Stringer, S., Melrose, J., and Whitelock, J. (2002) Not All perlecans are created equal. J. Biol. Chem., 277, 14657-14665.
24. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, J.T., Schols, L., and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet., 18, 106-108.
25. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A., 95, 6448-6453.
26. Lee, H.-J. and Lee, S.-J. (2002) Characterization of cytoplasmic α-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem., 277, 48976-48983.
27. Lee, H.-J., Patel, S., and Lee, S.J. (2005) Intravesicular localization and exocytosis of α-synuclein and its aggregates. J. Neurosci., 25, 6016-6024.
28. LeVine, H.D. (1993) Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: Detection of amyloid aggregation in solution. Protein Sci., 2, 404-410.
29. Li, J., Uversky, V.N., and Fink, A.L. (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation and fibrillation of human α-synuclein. Biochemistry, 40, 11604-11613.
30. Li, J., Uversky, V.N., and Fink, A.L. (2002) Conformational behavior of human α-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T. Neurotoxicology, 23, 553-567.
31. Lindahl, B. and Lindahl, U. (1997) Amyloid-specific heparan sulfate from human liver and spleen. J. Biol. Chem., 272, 26091-26094.
32. Lindahl, B., Eriksson, L., and Lindahl, U. (1995) Structure of heparan sulphate from human brain, with special regard to Alzheimer's disease. Biochem. J., 306, 177-184.
33. Lundquist, K. and Schmidtchen, A. (2001) Immunohistochemical studies on proteoglycan expression in normal skin and chronic ulcers. Br. J. Dermatol., 144, 254-259.
34. McBride, P.A., Wilson, M.I., Eikelenboom, P., Tunstall, A., and Bruce, E.M. (1998) Heparan sulfate proteoglycan is associated with amyloid plaques and neuroanatomically targeted PrP pathology throughout the incubation period of scrapie-infected mice. Exp. Neurol., 149, 447-454.
35. McCubbin, W.D., Kay, C.M., Narindrasorasak, S., and Kisilevsky, R. (1988) Circular-dichroism studies on two murine serum amyloid A proteins. Biochem. J., 256, 775-783.
36. McLaurin, J., Franklin, T., Kuhns, W.J., and Fraser, P.E. (1999) A sulfated proteoglycan aggregation factor mediates amyloid-β-peptide fibril formation and neurotoxicity. Amyloid, 6, 233-243.
37. Naiki, H., Higuchi, K., Hosokawa, M., and Takeda, T. (1989) Fluorometric determination of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal. Biochem., 177, 244-249.
38. Narhi, L., Wood, S.J., Steavenson, S., Jiang, Y., Wu, G.M., Anafi, D., Kaufman, S.A., Martin, F., Sitney, K., Denis, P., and others. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem., 274, 9843-9846.
39. Nielsen, L., Khurana, R., Coats, A., Vyas, S., Frokjaer, S., Brange, J., Uversky, V.N., and Fink, A.L. (2001) The effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism. Biochemistry, 40, 6036-6046.
40. Odawara, T., Iseki, E., Li, F., Kosaka, K., and Ikeda, K. (1998) Heparan sulfate proteoglycans recognize ghost Pick bodies. Neurosci. Lett., 242, 120-122.
41. Perry, G., Richey, P., Siedlak, S.L., Galloway, P., Kawai, M., and Cras, P. (1992) Basic fibroblast growth factor binds to filamentous inclusions of neurodegenerative diseases. Brain Res., 579, 350-352.
42. Pike, C.J., Walencewicz, A.J., Glabe, C.G., and Cotman, C.W. (1991) In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res., 563, 311-314.
43. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., and others. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
44. Roskams, T., de Vos, R., David, G., Van Damme, B., and Desmet, V. (1999) Heparan sulphate proteoglycan expression in human primary liver tumours. J. Pathol., 185, 290-297.
45. Sanderson, R.D., Turnbull, J.E., Gallagher, J.T., and Lander, A.D. (1994) Fine structure of heparan sulfate regulates syndecan-1 function and cell behavior. J. Biol. Chem., 269, 13100-13106.
46. Scholefield, Z., Yates, E.A., Wayne, G., Amour, A., McDowell, W., and Turnbull, J.E. (2003) Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-secretase. J. Cell Biol., 163, 97-107.
47. Shashidharan, P., Good, P.F., Hsu, A., Perl, D.P., Brin, M.F., and Olanow, C.W. (2000) TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease. Brain Res., 877, 379-381.
48. Snow, A.D., Willmer, J., and Kisilevsky, R. (1987) Sulfated glycosaminoglycans: A common constituent of all amyloids? Lab. Invest., 56, 120-123.
49. Snow, A.D., Kisilevsky, R., Willmer, J., Prusiner, S.B., and DeArmond, S.J. (1989) Sulfated glycosaminoglycans in amyloid plaques of prion diseases. Acta Neuropathol. (Berl), 77, 337-342.
50. Snow, A.D., Wight, T.N., Nochlin, D., Koike, Y., Kimata, K., DeArmond, S.J., and Prusiner, S.B. (1990) Immunolocalization of heparan sulfate proteoglycans to the prion protein amyloid plaques of Gerstmann-Straussler syndrome, Creutzfeld-Jakob disease and scrapie. Lab. Invest., 63, 601-611.
51. Snow, A.D., Bramson, R., Mar., H., Wight, T.N., and Kisilevsky, R. (1991) A temporal and ultrastructural relationship between heparan sulfate proteoglycans and AA amyloid in experimental amyloidosis. J. Histochem. Cytochem., 39, 1321-1330.
52. Snow, A.D., Sekiguchi, R., Nochlin, D., Fraser, P., Kimata, K., Mizutani, A., Arai, M., Schreier, W.A., and Morgan, D.G. (1994) An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. Neuron, 12, 219-234.
53. Soto, C. (2003) Unfolding the role of protein misfolding in neurodegenerative diseases. Nat. Rev. Neurosci., 4, 49-60.
54. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840.
55. Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., and Roses, A.D. (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A., 90, 1977-1981.
56. Su, J.H., Cummings, B.H., and Cotman, C.W. (1992) Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimer's disease. Neuroscience, 51, 801-813.
57. Suzuki, N., Cheung, T.T., Cai, X.D., Odaka, A., Otvos, L. Jr., Eckman, C., Golde, T.E., and Younkin, S.G. (1994) An increased percentage of long beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science, 264, 1136-1140.
58. Tanzi, R.E., Gusella, J.F., Watkins, P.C., Bruns, G.A., St George-Hyslop, P., Van Keuren, M.L., Patterson, D., Pagan, S., Kurnit, D.M., and Neve, R.L. (1987) Amyloid beta protein gene: CDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science, 235, 880-884.
59. Tsen, G., Halfter, W., Kroger, S., and Cole, G.J. (1995) Agrin is a heparan sulfate proteoglycan. J. Biol. Chem., 270, 3392-3399.
60. Uversky, V.N. (2003) A protein-chameleon: Conformationaol plasticity of α-synuclein, a disordered protein involved in neurodegenerative disorders. J. Biomol. Struct. Dyn., 21, 211-234.
61. Uversky, V.N. and Fink, A.L. (2002) Biophysical properties of human α-synuclein and its role in Parkinson's disease. In Pandalai, S.G. (ed.), Recent Research Developments in Proteins. Transworld Research Network, Kerala, India, Vol. 1, pp. 153-186.
62. Uversky, V.N. and Fink, A.L. (2004) Conformational constraints for the amyloid fibrillation: The importance of being unfolded. Biochim. Biophys. Acta, 43, 5575-5582.
63. Uversky, V.N. and Fink, A.L. (in press) Folding and misfolding of α-synuclein. In Kahle, P. and Haass, C. (eds), Molecular Mechanisms in Parkinson's Disease. Landes Bioscience, Georgetown, Washington, DC.
64. Uversky, V.N., Li, J., and Fink, A.L. (2001) Evidence for a partially folded intermediate in α-synuclein fibril formation. J. Biol. Chem., 276, 10737-10744.
65. van Horssen, J., Otte-Holler, I., David, G., Maat-Schieman, M.L.C., van den Heuvel, L.P.W.J., Wesseling, P., de Waal, R.M.W., and Verbeek, M.M. (2001) Heparan sulfate proteoglycan expression in cerebrovascular amyloid β deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. Acta Neuropathol. (Berl), 102, 604-614.
66. van Horssen, J., de Vos, R.A., Steur, E.N., David, G., Wesseling, P., de Waal, R.M., and Verbeek, M.M. (2004) Absence of heparan sulfate proteoglycans in Lewy bodies and Lewy neurites in Parkinson disease brains. J. Alzheimers Dis., 6, 469-474.
67. Verbeek, M.M., Otte-Holler, I., van den Born, J., van den Heuvel, L.P., David, G., Wesseling, P., and de Waal, R.M. (1999) Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain. Am. J. Pathol., 155, 2115-2125.
68. Volles, M.J., Lee, S.J., Rochet, J.C., Shtilerman, M.D., Ding, T.T., Kessler, J.C., and Lansbury, P.T. Jr. (2001) Vesicle permeabilization by protofibrillar alpha-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry, 40, 7812-7819.
69. Wakabayashi, K., Hayashi, S., Kakita, A., Yamada, M., Toyoshima, Y., Yoshimoto, M., and Takahashi, H. (1997) Accumulation of alpha-synuclein/ NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy. Acta Neuropathol. (Berl), 96, 445-452.
70. Winzen, U., Cole, G.J., and Halfter, W. (2003) Agrin is a chimeric proteoglycan with the attachment sites for heparan sulfate/chondroitin sulfate located in two multiple serine-glycine clusters. J. Biol. Chem., 278, 30106-20114.
71. Wood, S.J., Wypych, J., Steavenson, S., Louis, J.C., Citron, M., and Biere, A.L. (1999) Alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem., 274, 19509-19512.
72. Young, I.D., Ailles, L., Narindrasorasak, S., Tan, R., and Kisilevsky, R. (1992) Localization of the basement membrane heparan sulfate proteoglycan in islet amyloid deposits in type II diabetes mellitus. Arch. Pathol. Lab. Med., 116, 951-954.
73. Zebrower, M., Beeber, C., and Kieras, F.J. (1992) Characterization of proteoglycans in Alzheimer's disease fibroblasts. Biochem. Biophys. Res. Commun., 184, 1293-1300.
74. Zhou, W., Hurlbert, M.S., Schaack, J., Prasad, K.N., and Freed, C.R. (2000) Overexpression of human α-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res., 866, 33-43.
75. Zhou, W., Schaack, J., Zawada, W.M., and Freed, C.R. (2002) Over-expression of human α-synuclein causes dopamine neuron death in primary human mesencephalic culture. Brain Res., 926, 42-50.